glp-1 loss of muscle mass Weighing the risk treatment in older adults: Should we be concerned about sarcopenic obesity? Do GLP-1 medications really cause

O que dizem os estudos

The study included four groups ( n =10,896): nonusers of cannabis (61.0%), ex-users of cannabis (30.7%), light (once to four times/month

Their biological effects may be inappropriate for generalized metabolic disease but highly relevant for behaviorally mediated subtypes, reinforcing the need for stratified translational strategies

Conclusions Small molecule GLP-1 receptor agonists represent an innovative advancement in the management of T2DM and obesity

R., Hassanin, H., Skene, D

Improved glucose metabolism and insulin signalling in the brain: Alzheimers is sometimes described as type 3 diabetes because insulin resistance in neural tissue appears to promote pathology